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Enzyme-Mediated Dual-Targeted-Assembly Achieves Synergetic 
Anticancer Effect  
Dingze Mang,a,† Shijin Zhang,a,† Xia Wu,a Xunwu Hu,a Toshiaki Mochizuki,b Guanying Lia and Ye 
ZHang*,a 
We designed and synthesized homochiral-peptide-based boron 
diketonate complexes. Co-administration of the two 
stereoisomers on cancer cells let to molecular assembly targeting 
both the plasma membrane and the lysosomes mediated via 
membrane-bonded enzymes. The dual-targeted-assembly 
generates synergestic anticancer effect with amplified cancer 
spheroid toxicity and enhanced inhibition efficacy on cancer cell 
migration. 
Combination treatments are the current trend leading anti-
cancer drug research and development. Compared to single 
drugs, drug combinations, with multiple targets, offer a means 
to simplify complex treatment regimes with a better chance of 
affecting the equilibrium of cellular networks to cure complex 
diseases.1 Greater efficacy of combination treatments using 
particular small molecule drug combinations compared with 
higher dose single drugs has been identified.3 Although 
molecular assembly (MA) has been applied in the development 
of combination therapy, nano-encapsulations as carriers for 
the delivery of multiple small molecule drugs were the only 
reported applications.4, 5 Plasma-membrane-targeted MA has 
been established progressively as promising drug design to 
induce programmed cancer cell death.6, 7 Considering the 
initiation or amplification effects of lysosomal membrane 
permeabilization  (LMP)8 on the cell death program,9, 10 we 
intend to incorporate molecular assemblies of plasma 
membrane targeting with lysosome targeting for a 
synchronized anti-cancer effect.11 As shown in Figure 1, co-
administration of two precursor molecules leads to plasma 
membrane and lysosome dual-targeted molecular assemblies 
12 mediated via membrane enzyme–placental alkaline 
phosphatase (PLAP)13 that is highly expressed in cervical tumor 
as cancer biomarker. The programmed cancer cell death is 
promoted and amplified efficacy is achieved. 
Figure 1. (A) Schematic illustration of enzyme-mediated dual-targeted MAs in vitro. 
Mediated via enzymes highly expressed on the plasma membrane of cancer cells, co-
administration of molecular precursors induces MA targeting of both the plasma 
membrane and lysosomes. (B) Chemical structures of precursor molecules 1 and 2. 
Hydrolysed by ALP, 1 and 2 convert to 1’ and 2’, respectively, initiating MA with AIE.  
To construct multiple targeting MAs, synthetic peptides with 
impressive chiral recognition abilities14 are applied as main 
building blocks of precursor molecules for protein-guided MA 
with high precisions in vitro.15 A pair of homochiral peptides, 
Napthalene-pTyr-Phe-Lys-taurine and Napthalene-ptyr-phe-lys-
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taurine, coupled with the aggregation-induced emission (AIE) 
enhancement building block–boron diketone16 on the side 
chain of lysine are synthesized to obtain a pair of 
stereoisomers 1 and 2 (Figure 1). Via alkaline phosphatase 
(ALP)-catalysed hydrolysis, 1 and 2 can convert to assembly 
building blocks 1’ and 2’, respectively. With fluorescence 
induced by MA, we will be able to track the localization of MA 
in vitro. 
Under UV light, phosphate buffered saline (PBS) solutions of 1 
or 2 were lit up by emitting blue light following the addition of 
ALP (Figure 2A). After hydrolysis is completed (confirmed by 
LCMS), we characterized the MA using transmission electron 
microscopy (TEM) and circular dichroism (CD) spectroscopy. 
Compared to PBS solutions of 1 or 2 at the concentration of 
100 μM without MA, we found uniform nanofibers with 
around 6 nm in width tangling into dense networks after ALP-
catalysed hydrolysis (Figure 2B), and short strands of 
nanothread with much lower density (Figure 2C), respectively. 
The CD spectrum of 1 in PBS buffer shows a negative peak at 
210 nm and a positive peak at 220 nm (Figure S1). The CD 
spectrum of 2 in PBS buffer is the specular image of 1, which is 
consistent with the chirality of both molecules’ peptide 
building blocks.17 After ALP-catalysed hydrolysis, the CD 
spectra of the two solutions show a negative peak and a 
positive peak centred at 231 nm, respectively, indicating that 
the chirality of the peptide building blocks is transferred 
supramolecularly to the assembled nanostructures.18 
Figure 2. (A) Optical images of molecules 1 and 2 before and after the ALP catalysed 
hydrolysis in PBS buffer at the concentration of 100 μM under UV light. TEM images of 
1 (B) and 2 (C) in PBS buffer at the concentration of 100 μM by the end of their ALP 
catalysed hydrolysis. Scale bar is 100 nm. (D) Emission spectra of 1 and 2 before 
(labelled as 1, 2) and after (labelled as 1 + ALP, 2 + ALP) the ALP catalysed hydrolysis, 1' 
and 2' in PBS buffer at the concentration of 100 μM excited at 350 nm. (E) Kinetic 
profiles of enzyme catalysed hydrolysis of 1 and 2 in plasma membrane fraction and 
cytosolic fraction of HeLa cells at 37 °C. 
The difference in MAs is also reflected by their AIE intensities 
(Figure 2D). Excited at 350 nm (Figure S2), PBS solutions of 1 or 
2 show no MAs. Thus, both solutions exhibit weak emissions 
around 420 nm. Because of the same chemical structures, 1' 
and 2' in PBS solutions show enhanced fluorescence with 
similar intensities by forming identical uniform nanofibers via 
direct MA (Figure S3). Mediated via enzyme-catalysed 
hydrolysis, the induced MA of different chiral molecules 
promotes fluorescent intensities to different levels. For 
example, after the addition of ALP, the fluorescence intensity 
of PBS solution of 1 is 5 times higher than the PBS solution of 
2, which is consistent with their enzyme-induced MA 
performance (Figure 2B and 2C). The results suggest that 
enzyme-mediation can differentiate chiral molecules 1 and 2 
into divergent MAs leading to distinct nanostructures different 
from direct assembly of 1' and 2'. 
Figure 3. (A) Fluorescent image of HeLa cells incubated with 1 (100 μM, 12 h) and co-
stained with CellMask Red. (B) SEM image of HeLa cells incubated with 1 (100 μM, 12 
h). (C) Fluorescent image of HeLa cells incubated with 2 (100 μM, 12 h) and co-stained 
with LysoTracker Red. (D) TEM image of lysosomes isolated from HeLa cells incubated 
with 2 (100 μM, 12 h). Fluorescent image of HeLa cells incubated with the mixture of 1 
and 2  (1:1, total concentration 100 μM, 12 h) without (E) and with (F) PLAP inhibition, 
and co-stained with CellMask Red.  
To characterize the hydrolysis kinetics of both molecules 1 and 
2 in vitro, we monitored their composition changes in isolated 
plasma membrane fraction and cytosolic fraction of HeLa cells 
at 37 °C (Figure 2E and S4). In plasma membrane fraction, 1 
was hydrolysed faster than 2, and 2 was hydrolysed faster in 
cytosolic fraction than in plasma membrane fraction. 
Combined with the higher density of stable nanostructures 
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induced by enzyme-catalysed hydrolysis of 1, it has a better 
chance to induce MA on plasma membrane before entering 
into cells than 2. 
To examine the enzyme-mediated MA in vitro, we cultured 
HeLa cells that highly express PLAP on the plasma membrane 
for cell imaging. After 12-hour incubation with 1, fluorescent 
patches are observed on the plasma membrane (Figure 3A). 
Scanning electron microscopy imaging confirmed the 
formation of MAs on HeLa cell membrane (Figure 3B). After 
12-hour incubation with 2, fluorescent signals are observed 
inside the cells and co-localize with lysosomes (Figure 3C). The 
TEM image of isolated lysosomes exhibits nano-aggregates 
suggesting the formation of MAs in lysosomes (Figure 3D and 
S5). Co-administration of 1 and 2 at 1:1 ratio in HeLa cell 
culture for 12 hours induced fluorescent signals both on 
plasma membrane and in lysosomes indicating the success of a 
dual-targeted MA (Figure 3E).  Inhibiting the PLAP activity,19 
co-administration of 1 and 2 did not induce MA on the plasma 
membrane or in the cytoplasm of HeLa cells suggesting that 
the PLAP is essential in enzyme-mediated dual-targeted MA. 
 
Figure 4. (A) Schematic illustration of simplified extrinsic and intrinsic apoptotic 
pathways. (B) Western blotting for Caspase-8 and Caspase-9 expressed in HeLa cells 
under the treatment of 1, 2 and mixture of 1 and 2 at 1:1 ratio. GAPDH is a loading 
control. Time-dependent expression profiles of cleaved forms of caspase-8 (cl. Caspase-
8) (C), and cleaved forms of caspase-9 (cl. Caspase-9) (D) in HeLa cells under the 
treatment of 1, 2 and mixture of 1 and 2 at 1:1 ratio. Results are means ± S.D. of three 
independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001. 
Single-administration and co-administration of 1 and 2 on HeLa 
cells both triggered apoptotic pathways (Figure S6). Most 
apoptotic programs fall into either the extrinsic or intrinsic 
category triggered by extracellular cues or intracellular stimuli.  
The extrinsic pathway is mediated by caspase-8 while the 
intrinsic pathway is mediated by caspase-9 (Figure 4A).20 The 
activities of both caspases were evaluated by western blotting 
(Figure 4B).  As shown in Figure 4C, after 24-hour incubation, 
HeLa cells under the treatment of 1 showed 20% higher 
expression level of cleaved caspase-8 than under the 
treatment of 2. In Figure 4D, since 6-hour incubation, HeLa 
cells under the treatment of 2 showed obvious higher 
expression level of cleaved caspase-9 than under the 
treatment of 1. The activation of both caspases induced by two 
molecules is consistent with their subcellular targets. HeLa 
cells under the co-treatment of 1 and 2 show higher 
expression levels of both cleaved caspase-8 and cleaved 
caspase-9 than both single administrations of two molecules. 
For example, 6-hour co-administration of 1 and 2 induce HeLa 
cells express similar amount of cleaved caspase-8 and cleaved 
caspase-9 as 12-hour single-administration with the same total 
concentration. The comparisons indicated that dual-targeted 
MA induced by co-administration of 1 and 2 promotes the cell 
death program with amplified apoptotic effect. 
To evaluate the anti-cancer efficacy of dual-targeted MA, we 
examined the HeLa cell viability under the co-administration of 
1 and 2 compared to their single-administrations. In 2D HeLa 
cell culture, D-version peptide molecule 2 showed higher 
toxicity than 1,21 while co-administration of 1 and 2 exhibited 
similar toxicity as single-administration of 2 (Figure S7A). Co-
administration exhibited enhanced anti-cancer efficacy in 3D 
cell cultures compare to single-administrations. As shown in 
Figure 5A at total concentration of 50 μM, co-administration 
started exhibiting lower cell viability than single-
administrations after 24-hour cell incubation. After another 48 
hours, the cell viability of co-administration dropped to 70%, 
while the cell viability of single-administrations remain the 
same as 24-hour incubation at 85-90%. At total concentration 
of 100 μM, co-administration reached similar toxicity as single-
administrations at 200 μM after 72-hour incubation. The 
toxicity of dual-targeted MA was also examined on stromal 
cells (HS-5) and normal epithelial cells (Ect1/E6E7) (Figure S7B 
and S7C). 1 is biocompatible, while 2 shows certain toxicity on 
both cell lines. Without PLAP expression, both molecules 
target lysosomes of the cells (Figure S8). Co-administration 
exhibited median value toxicity of both single administrations 
being relatively biocompatible. 
Figure 5. (A) HeLa cell over a 3-day period of incubation with 1, 2 and mixture of 1 and 
2 at 1:1 ratio at various concentrations in 3D cell culture. (B) Time-lapse optical images 
of HeLa spheroids with and without the treatment of 1 and 2 mixture at 1:1 ratio at 
total concentration of 100 μM. (C) Time-dependent area size of Hela cell spheroids 
incubated with 1, 2 and mixture of 1 and 2 at 1:1 ratio at various concentrations. 
Compared to the 90% closure rate of the control wound 
healing experiment, single-administration of 1 at 50 μM and 
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100 μM concentrations resulted in 48% and 30% closure rates 
(Figure S7B and S8), while single-administration of 2 resulted in 
40% and 20% closure rates, respectively (Figure S7B and S9).  
Co-administration at the same total concentrations led to 38% 
and 16% closure rates, respectively (Figure S7B and S10). 
Apparently, co-administration shows slightly higher inhibition 
efficacy than both single-administrations in 2D cell culture. In 
3D cell culture, co-administration exhibited strong inhibition 
efficacy in the migration of HeLa spheroids (Figure 5B), 
superior to single-administrations. HeLa spheroids under the 
treatment of 1 at concentrations of 50 μM and 100 μM exhibit 
87% and 78% of the total area of the control experiment after 
72 hours, respectively (Figure 5C and S11). Under the 
treatment of 2 at the same concentrations, HeLa spheroids 
expand to 87% and 71% of the total area of the control 
experiment after 72 hours.  Co-administration of 1 and 2 (1:1) 
at the same total concentrations resulted into spheroids with 
only 64% and 54% of the total area of the control experiment 
after 72 hours. Co-administration at total concentration of 50 
μM showed higher inhibition efficacy on HeLa spheroid 
expansion than single-administrations at a concentration of 
100 μM. 
PLAP has been reported as tumor biomarker with elevated 
expression levels in tissues.22 PLAP expression of HeLa cells in 
different culture conditions was examined using imaging flow 
cytometry. In 3D cell culture, PLAP expression of HeLa cells is 
twice as high as in 2D cell culture (Figure S12). Since PLAP is 
essential in enzyme mediated dual-targeted MA, higher 
expression level may contribute to the greater anti-cancer 
efficacy of co-administration in 3D cell culture than in the 2D 
condition. Overall, greater anti-cancer efficacy of using 1 and 2 
combinations for dual-targeted MAs compared with higher 
dose single molecule is identified on both cytotoxicity and 
migration inhibition of cervical cancer cells.  
Conclusions 
Enzyme-mediated plasma membrane and lysosome dual 
targeted MA introduces synergetic anti-cancer effect with 
amplified efficacy. It opens new opportunities in the 
application of nanotechnology for combination treatment. The 
differentiation of chiral molecules for divergent MA via 
enzyme-mediation in vitro also exhibits the advantages of 
using combinations of chiral peptides in drug design to avoid 
medication errors caused by drug-drug interactions.23 
Although the sequential engagement and mutual interactions 
are currently unclear, this research will contribute to 
comprehensive thought in protein interaction involved 
molecular assembly for advanced applications in cancer 
research. 
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